nach oben

Diabetologia

Erschienen in:

01.03.2009 | Article

Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain

verfasst von: O. Heikkilä, N. Lundbom, M. Timonen, P.-H. Groop, S. Heikkinen, S. Mäkimattila

Erschienen in: Diabetologia | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of the study was to assess the effect of hyperglycaemia on regional concentrations of glucose and other substrates within the brain in non-diabetic individuals and in patients with type 1 diabetes.

Methods

The brain metabolites of 17 men with type 1 diabetes and 12 age-matched non-diabetic men (22–43 years old) were studied after an overnight fast (plasma glucose 9.2 ± 3.0 vs 4.8 ± 0.5 mmol/l, respectively). N-Acetylaspartate (NAA), creatine, choline, myo-inositol (mI) and glucose in the frontal cortex, frontal white matter and thalamus were quantified with proton magnetic resonance spectroscopy.

Results

In the non-diabetic participants, the glucose level was 47% higher (p < 0.01) in the frontal cortex than in the frontal white matter. In contrast, this regional variation was not observed in the diabetic participants, in whom the glucose level in the frontal white matter was 64% higher (p < 0.001) and in the frontal cortex 25% higher (p = 0.033) than that of the non-diabetic participants. In the diabetic participants, the glucose level in each of the three regions studied correlated with fasting plasma glucose (r = 0.88–0.67, p < 0.01). In addition, in the diabetic participants, mI was 20% higher (p < 0.001) and NAA 6% lower (p = 0.037) in the frontal white matter, and mI was 8% higher (p = 0.042) in the frontal cortex, than in the non-diabetic participants.

Conclusions/interpretation

In type 1 diabetes, hyperglycaemia is associated with accumulation of glucose and mI in the cortex and in the white matter.

McCall AL (1992) The impact of diabetes on the CNS. Diabetes 41:557–570PubMedCrossRef

van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ (2006) Brain imaging in patients with diabetes: a systematic review. Diabetes Care 29:2539–2548PubMedCrossRef

Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP (2005) The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 28:726–735PubMedCrossRef

Keymeulen B, Jacobs A, de Metz K, de Sadeleer C, Bossuyt A, Somers G (1995) Regional cerebral hypoperfusion in long-term type 1 (insulin-dependent) diabetic patients: relation to hypoglycaemic events. Nucl Med Commun 16:10–16PubMedCrossRef

Quirce R, Carril JM, Jimenez-Bonilla JF et al (1997) Semi-quantitative assessment of cerebral blood flow with ^99mTc-HMPAO SPET in type I diabetic patients with no clinical history of cerebrovascular disease. Eur J Nucl Med 24:1507–1513PubMedCrossRef

Laing SP, Swerdlow AJ, Carpenter LM et al (2003) Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 34:418–421PubMedCrossRef

Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef

Musen G, Lyoo IK, Sparks CR et al (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55:326–333PubMedCrossRef

Wessels AM, Simsek S, Remijnse PL et al (2006) Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 49:2474–2480PubMedCrossRef

10.

Wessels AM, Scheltens P, Barkhof F, Heine RJ (2008) Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. Eur J Pharmacol 585:88–96PubMedCrossRef

11.

Cox DJ, Kovatchev BP, Gonder-Frederick LA et al (2005) Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 28:71–77PubMedCrossRef

12.

Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256–266PubMedCrossRef

13.

Sarac K, Akinci A, Alkan A, Aslan M, Baysal T, Ozcan C (2005) Brain metabolite changes on proton magnetic resonance spectroscopy in children with poorly controlled type 1 diabetes mellitus. Neuroradiology 47:562–565PubMedCrossRef

14.

Wootton-Gorges SL, Glaser NS (2007) Imaging of the brain in children with type I diabetes mellitus. Pediatr Radiol 37:863–869PubMedCrossRef

15.

Kreis R, Ross BD (1992) Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus: detection with proton MR spectroscopy. Radiology 184:123–130PubMed

16.

Mäkimattila S, Malmberg-Ceder K, Häkkinen AM et al (2004) Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J Cereb Blood Flow Metab 24:1393–1399PubMedCrossRef

17.

Cameron FJ, Kean MJ, Wellard RM, Werther GA, Neil JJ, Inder TE (2005) Insights into the acute cerebral metabolic changes associated with childhood diabetes. Diabet Med 22:648–653PubMedCrossRef

18.

Geissler A, Frund R, Scholmerich J, Feuerbach S, Zietz B (2003) Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. Exp Clin Endocrinol Diabetes 111:421–427PubMedCrossRef

19.

Criego AB, Tkac I, Kumar A, Thomas W, Gruetter R, Seaquist ER (2005) Brain glucose concentrations in patients with type 1 diabetes and hypoglycemia unawareness. J Neurosci Res 79:42–47PubMedCrossRef

20.

Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39:233–252PubMed

21.

McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M (1976) Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41:565–573PubMedCrossRef

22.

Urrila AS, Hakkarainen A, Heikkinen S et al (2006) Preliminary findings of proton magnetic resonance spectroscopy in occipital cortex during sleep deprivation. Psychiatry Res 147:41–46PubMedCrossRef

23.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed

24.

Campbell MJ, Julious SA, Altman DG (1995) Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 311:1145–1148PubMed

25.

Ferguson SC, Blane A, Wardlaw J et al (2005) Influence of an early-onset age of type 1 diabetes on cerebral structure and cognitive function. Diabetes Care 28:1431–1437PubMedCrossRef

26.

Schoenle EJ, Schoenle D, Molinari L, Largo RH (2002) Impaired intellectual development in children with type I diabetes: association with HbA(1c), age at diagnosis and sex. Diabetologia 45:108–114PubMedCrossRef

27.

Rasgon NL, Thomas MA, Guze BH et al (2001) Menstrual cycle-related brain metabolite changes using 1H magnetic resonance spectroscopy in premenopausal women: a pilot study. Psychiatry Res 106:47–57PubMedCrossRef

28.

Lincoln NB, Faleiro RM, Kelly C, Kirk BA, Jeffcoate WJ (1996) Effect of long-term glycemic control on cognitive function. Diabetes Care 19:656–658PubMedCrossRef

29.

Ryan CM, Geckle MO, Orchard TJ (2003) Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia 46:940–948PubMedCrossRef

30.

Ferguson SC, Blane A, Perros P et al (2003) Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 52:149–156PubMedCrossRef

31.

Ryan CM, Williams TM, Finegold DN, Orchard TJ (1993) Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 36:329–334PubMedCrossRef

32.

Bonora E (2006) The metabolic syndrome and cardiovascular disease. Ann Med 38:64–80PubMedCrossRef

33.

Li C, Hedblad B, Rosvall M, Buchwald F, Khan FA, Engstrom G (2008) Stroke incidence, recurrence, and case-fatality in relation to socioeconomic position: a population-based study of middle-aged Swedish men and women. Stroke 39:2191–2196PubMedCrossRef

34.

Seaquist ER, Damberg GS, Tkac I, Gruetter R (2001) The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans. Diabetes 50:2203–2209PubMedCrossRef

35.

Heiss WD, Habedank B, Klein JC et al (2004) Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med 45:1811–1815PubMed

36.

Mason GF, Pan JW, Chu WJ et al (1999) Measurement of the tricarboxylic acid cycle rate in human grey and white matter in vivo by ¹H-[¹³C] magnetic resonance spectroscopy at 4.1T. J Cereb Blood Flow Metab 19:1179–1188PubMedCrossRef

37.

de Graaf RA, Pan JW, Telang F et al (2001) Differentiation of glucose transport in human brain gray and white matter. J Cereb Blood Flow Metab 21:483–492PubMedCrossRef

38.

Eisenberg F Jr, Parthasarathy R (1987) Measurement of biosynthesis of myo-inositol from glucose 6-phosphate. Methods Enzymol 141:127–143PubMedCrossRef

39.

Ross B, Bluml S (2001) Magnetic resonance spectroscopy of the human brain. Anat Rec 265:54–84PubMedCrossRef

40.

Strange K, Emma F, Paredes A, Morrison R (1994) Osmoregulatory changes in myo-inositol content and Na⁺/myo-inositol cotransport in rat cortical astrocytes. Glia 12:35–43PubMedCrossRef

41.

Urenjak J, Williams SR, Gadian DG, Noble M (1992) Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 59:55–61PubMedCrossRef

42.

Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45:37–45PubMedCrossRef

43.

Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81:89–131PubMedCrossRef

44.

Wessels AM, Rombouts SA, Remijnse PL et al (2007) Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. Diabetologia 50:1763–1769PubMedCrossRef

45.

Kodl CT, Franc DT, Rao JP et al (2008) Diffusion tensor imaging (DTI) identifies deficits in white matter microstructure in subjects with type 1 diabetes mellitus that correlate with reduced neurocognitive function. Diabetes 57:3083–3089PubMedCrossRef

Titel: Hyperglycaemia is associated with changes in the regional concentrations of glucose and myo-inositol within the brain
verfasst von: O. Heikkilä
N. Lundbom
M. Timonen
P.-H. Groop
S. Heikkinen
S. Mäkimattila
Publikationsdatum: 01.03.2009
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 3/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-008-1242-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Guidelines for medical management of hyperglycaemia in type 2 diabetes and duality of interest

Diabetes dietary management alters responses to food pictures in brain regions associated with motivation and emotion: a functional magnetic resonance imaging study

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms

Medical management of hyperglycaemia in type 2 diabetes mellitus. Reply to Woo V [letter] and Eizirik DL [letter]